Profile data is unavailable for this security.
About the company
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
- Revenue in CHF (TTM)141.42m
- Net income in CHF-55.88m
- Incorporated2017
- Employees938.00
- LocationIdorsia LtdHegenheimermattweg 91ALLSCHWIL 4123SwitzerlandCHE
- Websitehttps://www.idorsia.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Santhera Pharmaceuticals Holding AG | 103.38m | 54.78m | 124.61m | 46.00 | -- | 1.85 | -- | 1.21 | -17.28 | -17.28 | 9.14 | 5.34 | 1.19 | 3.37 | 63.69 | -- | 63.20 | -33.83 | 136.70 | -52.56 | 96.87 | 86.74 | 52.99 | -79.40 | 0.75 | 3.57 | 0.2628 | -- | 1,283.33 | 26.70 | 177.08 | -- | 1.87 | -- |
| Molecular Partners AG | 6.73m | -58.53m | 124.72m | 168.00 | -- | 0.663 | -- | 18.54 | -1.78 | -1.78 | 0.2043 | 5.13 | -- | -- | -- | 40,035.71 | -- | -11.83 | -- | -14.69 | -- | 99.28 | -870.22 | -45.30 | -- | -- | 0.0195 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
| Newron Pharmaceuticals SpA | 8.86m | -15.86m | 186.32m | 23.00 | -- | -- | -- | 21.04 | -0.8889 | -0.8889 | 0.4963 | -1.64 | 0.2873 | -- | 4.57 | 385,022.60 | -51.45 | -37.10 | -111.53 | -43.98 | 94.80 | 91.72 | -179.13 | -270.48 | -- | -2.86 | 2.62 | -- | 48.62 | 17.61 | 7.25 | -- | -22.76 | -- |
| Xlife Sciences AG | 988.44k | 14.88m | 188.21m | 17.00 | 27.10 | 0.6882 | 7.44 | 190.41 | 1.22 | 1.22 | 0.1382 | 47.95 | 0.002 | -- | 0.2044 | 58,143.53 | 1.85 | -- | 2.33 | -- | 45.43 | -- | 938.17 | -- | -- | -- | 0.1345 | -- | -3.85 | -- | 3.96 | -- | -- | -- |
| Kuros Biosciences AG | 33.56m | -13.73m | 341.16m | 80.00 | -- | 5.99 | -- | 10.16 | -0.3697 | -0.3697 | 0.9175 | 1.54 | 0.4347 | 2.40 | 7.27 | 419,550.00 | -17.78 | -13.47 | -21.34 | -14.84 | 71.31 | 78.73 | -40.90 | -81.48 | 1.69 | -84.04 | 0.0364 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| Idorsia Ltd | 141.42m | -55.88m | 490.18m | 938.00 | -- | -- | -- | 3.47 | -0.3534 | -0.3534 | 0.7363 | -4.97 | 0.1912 | 0.1645 | 113.09 | 150,766.50 | -7.56 | -46.72 | -12.46 | -53.84 | 93.05 | -- | -39.51 | -709.80 | 1.00 | -26.26 | 5.82 | -- | 56.93 | 20.25 | 64.01 | -- | -8.01 | -- |
| Basilea Pharmaceutica AG Allschwil | 157.63m | 10.45m | 575.52m | 147.00 | 49.86 | -- | 47.76 | 3.65 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Polypeptide Group AG | 317.63m | -50.30m | 1.11bn | 1.20k | -- | 2.95 | -- | 3.48 | -1.52 | -1.52 | 9.59 | 11.31 | 0.5137 | 2.31 | 5.08 | 264,248.20 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| Cosmo Pharmaceuticals NV | 94.57m | 1.12m | 1.24bn | 325.00 | 1,016.72 | 2.72 | 81.39 | 13.13 | 0.0696 | 0.0696 | 5.86 | 25.99 | 0.1473 | 3.06 | 2.88 | 290,988.70 | 0.2051 | 0.2437 | 0.249 | 0.267 | 59.33 | 57.28 | 1.39 | 2.10 | 3.80 | 2.73 | 0.0042 | 841.86 | -5.26 | 8.07 | -93.34 | -- | 9.62 | -- |
| BB BIOTECH AG | 270.74m | 307.74m | 2.21bn | -- | 7.11 | 0.8856 | -- | 8.17 | 5.62 | 5.62 | 4.91 | 45.11 | 0.0998 | -- | -- | -- | 11.35 | 2.34 | 12.96 | 2.52 | 97.74 | 99.06 | 113.67 | 35.40 | -- | -- | 0.1223 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
Data as of May 31 2024. Currency figures normalised to Idorsia Ltd's reporting currency: Swiss Franc CHF
17.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 5.47m | 2.90% |
| Lazard Asset Management Ltd.as of 13 Jan 2023 | 5.32m | 2.82% |
| Astaris Capital Management LLPas of 25 Apr 2024 | 4.89m | 2.59% |
| The Vanguard Group, Inc.as of 09 May 2024 | 4.33m | 2.29% |
| UBS Asset Management Switzerland AGas of 07 May 2024 | 4.30m | 2.28% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 3.17m | 1.68% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 2.61m | 1.38% |
| Z�rcher Kantonalbank (Investment Management)as of 28 Mar 2024 | 1.72m | 0.91% |
| Rossier, Mari & Associates AGas of 31 Mar 2024 | 1.05m | 0.56% |
| Banque Cantonale de Gen�ve (Investment Management)as of 31 Dec 2023 | 785.56k | 0.42% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
